FDA expands use of remdesivir to patients with high risk of hospitalization

FILE PHOTO: A laboratory technician shows Remdesivir, a drug used in the treatment of the coronavirus disease (COVID-19), at Eva Pharma facility in Cairo, Egypt June 1, 2021. Picture taken June 1, 2021. REUTERS/Mohamed Abd El Ghany

(Reuters) – The U.S. health regulator on Friday expanded its approval for the use of Gilead Sciences’ antiviral drug remdesivir to treat non-hospitalized patients 12 years and older for the treatment of mild-to-moderate COVID-19 disease with high risk of hospitalization.

Previously, the use of Veklury was limited to patients requiring hospitalization.

Source: Read Full Article